In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –– Reduced secured and convertible debt by 90% from ...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...

Rising NEC Incidence: The global increase in diagnosed cases of neuroendocrine tumors (including carcinomas) is a major market growth driver. This uptick is driven by better detection and reporting, ...

Earnings call Coherus Oncology doubled LOQTORZI sales to $40.8M in 2025 (113% YoY growth), achieved a 90%+ debt reduction, and completed its transformation into a focused oncology innovator.

TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM ESTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...

Colorectal cancer is increasing in younger patients and is now the leading cause of cancer death in those under age 50, yet those patients lack support.

Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary ...

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has been successfully dosed in a Phase ? clinical study ...